Monoclonal antibodies (mAbs) are attractive therapeutic tools, being highly specific for their targets. However, immunogenicity, the potential of a therapeutic antibody to provoke an immune response, remains a risk.

Nov 20, 2024

If you don’t find what you need, let us know with a message.

We'll respond as soon as possible to assist you!

You can also contact us on the Scientist and Science Exchange marketplaces.

Services
- Antibody Discovery
  
  VHH Antibody Discovery Single B Cell Screening Hybridoma Sequencing High-throughput Fully Human Antibody Discovery Platform ^New!
- Antibody Optimization
  
  Affinity Maturation Antibody Humanization
- Recombinant Protein Expression
  
  Recombinant Protein Expression in Mammalian Cells & E.coli
- Antibody Production
  
  HTP Recombinant Antibody Production Bispecific Antibody Production Large Scale Antibody Production Afucosylated Antibody Expression RushMab™ - Small Scale Expression Packages ADC High-throughput Antibody Conjugation ^New!
- Stable Cell Line
  
  CHO-K1 Stable Cell Line Generation Commercial License for CHOK1BN
Products
Resources
About Us
Contact
- Contact
- Distributors